Alzheimer's Disease Neuroimaging Initiative 3 (ADNI 3)

ADNI 3Courtesy of the USC Laboratory of Neuro Imaging and Athinoula A. Martinos Center for Biomedical Imaging,
Consortium of the Human Connectome Project.

The Alzheimer’s Disease Neuroimaging Initiative (ADNI), is a landmark partnership and study that for years has profoundly influenced our understanding of Alzheimer’s disease (AD) by identifying the earliest changes in brain structure and function that signal its onset and progression. The study is led by the National Institute on Aging with support from the FNIH and more than 30 organizations since its launch in 2004.

The third phase of ADNI launched in September 2016, building on the success of previous phases with new additions, including:

  • Recruiting up to a total of 1,200 volunteers, including the approximately 500 current rollover participants to enrich the existing dataset;
  • Using state-of-the-art PET imaging techniques to monitor brain levels of tau, a protein that is often abnormal in Alzheimer’s patients;
  • Performing cutting-edge systems biology analyses to holistically assess complex interactions between the brain and body;
  • Assessing cognitive function through computer tests at home and in the doctor’s office and measure changes in subjects’ ability to handle money via the Financial Capacity Instrument Short Form (FCI-SF), which can be a warning sign of the disease.

ADNI 3 will run until July 31, 2022.

Read about the second phase of ADNI (ADNI 2) here

Read this information on ADNI from the National Institute of Aging.

Through the support of the ADNI Private Partner Scientific Board, the Amyloid PET Early Frames substudy is currently in fundraising for incorporation into ADNI3. The overall goal of the Amyloid PET Early Frames study is to determine if blood flow in the brain, measured by PET early frame measurements, can be used as a measure of cognitive decline. This project proposes to do this by measuring the spread of a PET tracer in subjects’ brains immediately after introduction into the body. This will be done in a minimum of 100 subjects at two different time intervals, 2 years apart, to assess differences over time. Additionally, the subjects will be split among healthy controls and individuals with Mild Cognitive Impairment (MCI) to understand differences in the two populations. If successful, this project could reduce patient burden in AD clinical trials by eliminating the need for a separate FDG PET scan, thus minimizing trips to the clinic and unnecessary radiation exposure. This would also be a huge advantage to drug developers as it would reduce clinical trial costs enabling the costs to be spent on additional patients or other trials. 

Goals

  • To detect Alzheimer's Disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers
  • To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods, to apply at the earliest stages technically possible - when intervention may be most effective
  • To continually develop ADNI's data access policy and continuously improve and expand the unprecedented data sharing model

Results & Accomplishments

Scientific Publications

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; et al. Alzheimer's Dis Neuroimaging ALZHEIMERS & DEMENTIA 2017 13(4): E1-E85

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 Weiner, Michael W.; Veitch, Dallas P.; Aisen, Paul S.; et al. Alzheimer's Dis Neuroimaging Initi ALZHEIMERS & DEMENTIA 2015 11(7): 865-884

Media

FNIH Press Release (Sept. 8, 2016): Patient Advocacy Groups, Industry and Individuals Join Groundbreaking Public-Private Partnership to Continue Advancing Critical Alzheimer's Disease Research

Support

The FNIH is currently seeking funding commitments to support this program. For more information, please contact Development@fnih.org. Learn about the ADNI 3 Partnership Overview here

Partners

Private-Sector Partners:
AbbVie*
ACT-AD*
Alector*
Alzheimer's Association*
Alzheimer's Drug Discovery Foundation*
Araclon Biotech*
BioClinica*
Biogen*
Cogstate*
Denali Therapeutics*
Diamir*
Eisai Inc.*
Euroimmun*
Eli Lilly and Company*
FUJIFILM Toyama Chemical Co., Ltd.*
Genentech, a member of the Roche Group*
GE Healthcare*
Janssen Research & Development, LLC*
Lundbeck*
MagQu*
Merck Sharpe & Dohme Corp.*
PeopleBio*
Pfizer, Inc.*
Piramal Imaging*
Roche*
Saladex Biomedical*
Servier*
Takeda*

*Provided financial or in-kind support for this program.

FNIH Contact

Rosa Canet-Aviles, Ph.D., Director, Neuroscience, Research Partnerships rcanet-aviles@fnih.org